Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z6RW
|
|||
| Former ID |
DIB011675
|
|||
| Drug Name |
LMP-1/LMP-2 CTLs
|
|||
| Synonyms |
Ad5f35LMPd1-2; LMP-1/LMP-2 CTLs, Baylor College of Medicine/NCI; LMP-1/LMP-2 specific cytotoxic T-lymphocytes (gene therapy,nasopharyngeal cancer/lymphoma), Baylor College of Medicine/NCI
Click to Show/Hide
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1 | [1] | |
| Company |
Baylor College of Medicine
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Epstein-Barr virus Latent membrane protein 1 (EBV LMP1) | Target Info | Modulator | [2] |
| Epstein-Barr virus Latent membrane protein 2 (EBV LMP2) | Target Info | Modulator | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00062868) LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May;47(5):837-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.